Publications by authors named "Primo Lara"

Claim this Profile
T
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).
Mamta Parikh, Nataliya V Uboha, Naoko Takebe, Kit Tam, Philippe L Bedard, Primo N Lara

Cancer Res Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.
Sarmad Sadeghi, Primo N Lara, Andrea Necchi, Parkash S Gill, Thomas W Flaig

JCO Oncol Pract· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer.
Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, Chao Zhang, Eva Rodansky, Primo Lara

NPJ Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.
Umang Swami, Yeonjung Jo, Arshit Narang, Melissa Plets, Chadi Hage Chehade, Primo N Lara

Eur Urol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer.
Alyssa Liang, Shuchi Gulati, Quillan Huang, Heidi Dowst, Aedric Lim, Primo N Lara

Endocr Relat Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.
Jonathan W Riess, Matthew S Lara, Guillaume Luxardi, Miguel Lopez de Rodas, Michiko Shimoda, Primo N Lara

JTO Clin Res Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis.
Matthew S Lara, Jonathan W Riess, Guneet Kaleka, Alexander Borowsky, John D McPherson, Primo N Lara

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Primo N Lara

Oncogene· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma.
Shuchi Gulati, Lorenzo Nardo, Primo N Lara

Eur Urol Focus· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson, Vivek Narayan, Primo N Lara

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant everolimus after renal cell carcinoma nephrectomy - Authors' reply.
Christopher W Ryan, Catherine M Tangen, Primo N Lara

Lancet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Primo N Lara

Eur Urol Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.
Abhishek Tripathi, Catherine M Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Primo N Lara

BJU Int· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Amir Goldkorn, Catherine Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Primo N Lara

JAMA Netw Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
Primo N Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn

Prostate Cancer Prostatic Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
Primo N Lara, Catherine Tangen, Elisabeth I Heath, Shuchi Gulati, Mark N Stein

Eur Urol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Andrea B Apolo, Daniel M Girardi, Scot A Niglio, Rosa Nadal, Andre R Kydd, Dilara Akbulut, Primo N Lara

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Primo N Lara

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
Shuchi Gulati, Catherine Tangen, Christopher W Ryan, Ulka N Vaishampayan, Brian M Shuch, Primo N Lara

JAMA Netw Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review.
Steven Monda, Primo N Lara, Shuchi Gulati

Kidney Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.
Georges Gebrael, Yeonjung Jo, Umang Swami, Melissa Plets, Chadi Hage Chehade, Primo N Lara

JAMA Netw Open· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
Primo N Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Primo N Lara

J Natl Compr Canc Netw· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023.
Shuchi Gulati, Primo Nery Lara

Kidney Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer.
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N Lara

Acta Pharm Sin B· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis